Report of Foreign Issuer (6-k)
April 07 2020 - 4:31PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
Form 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For
the month of April 2020
Commission
File Number 001-38370
CollPlant
Biotechnologies Ltd.
(Exact
name of registrant as specified in its charter)
4
Oppenheimer St, Weizmann Science Park
Rehovot
7670104, Israel
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
This
Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-229163)
and Form F-3 (File No. 333-229486 and 333-228054), to be a part thereof from the date on which this report is submitted, to the
extent not superseded by documents or reports subsequently filed or furnished.
On
April 7, 2020, CollPlant Biotechnologies Ltd. (the “Company”) announced that on May 14, 2020, it will hold at the
offices of Gross, Kleinhendler, Hodak, Halevy, Greenberg, Shenhav & Co. law firm, at One Azrieli Center, Round Building, 40th
Floor, Tel-Aviv, Israel, an extraordinary general meeting of shareholders (the “General Meeting”) at 10:00 a.m. Israel
time. In connection with the meeting, the Company furnishes the following documents:
|
1.
|
A
copy of the Notice and Proxy Statement with respect to the Company’s General Meeting describing the proposals to be voted
upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related to the meeting,
attached hereto as Exhibit 99.1;
|
|
2.
|
A
form of Proxy Card whereby holders of ordinary shares of the Company may vote at the meeting without attending in person, attached
hereto as Exhibit 99.2; and
|
|
3.
|
A
form of Voting Instruction Card whereby holders of ADSs of the Company may instruct Bank of New York Mellon to vote at the meeting
without attending in person, attached hereto as Exhibit 99.3.
|
In addition, a copy of the Company’s
updated Share Ownership and Option Plan (2010) is attached as Exhibit 99.4 hereto.
Exhibit
Index
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
COLLPLANT
BIOTECHNOLOGIES LTD.
|
|
|
|
Date:
April 7, 2020
|
By:
|
/s/
Eran Rotem
|
|
|
Name:
|
Eran Rotem
|
|
|
Title:
|
Deputy CEO and Chief Financial Officer
|
2
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From Sep 2023 to Sep 2024